Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Patients who are currently receiving a suppressive regimen of 2 NRTIs plus a PI and who harbor NRTI resistance mutations are at increased risk of virologic failure from switching to an NNRTI[Martínez 2003]
- NNRTIs have a low genetic barrier to resistance and must be supported by an active background regimen rather than one that has been weakened by the presence of NRTI resistance
- NNRTIs have a low genetic barrier to resistance and must be supported by an active background regimen rather than one that has been weakened by the presence of NRTI resistance
- In the SPIRIT trial, switching from ritonavir-boosted PI–based regimens to single-tablet emtricitabine/rilpivirine/tenofovir DF was noninferior to continued boosted PI–based therapy in patients with no history of previous treatment failure[Palella 2014]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Switch Strategies